Assessment of Quality of Life Among Patients With Recurrent Clostridioides difficile Infection Treated with Investigational Oral Microbiome Therapeutic SER-109
Sign Up to like & getrecommendations! Published in 2023 at "JAMA Network Open"
DOI: 10.1001/jamanetworkopen.2022.53570
Abstract: This secondary analysis of a randomized clinical trial examines the association of SER-109 with health-related quality of life in 182 patients with recurrent Clostridioides difficile infection in the US and Canada. read more here.
Keywords: recurrent clostridioides; clostridioides difficile; difficile infection; patients recurrent ... See more keywords
Safety and Tolerability of SER-109 as an Investigational Microbiome Therapeutic in Adults With Recurrent Clostridioides difficile Infection
Sign Up to like & getrecommendations! Published in 2023 at "JAMA Network Open"
DOI: 10.1001/jamanetworkopen.2022.55758
Abstract: This phase 3, open-label, single-arm trial assesses the safety of SER-109 and the rate of recurrent Clostridioides difficile infection after administration of SER-109 following symptom resolution after antibiotic treatment among adults. read more here.
Keywords: recurrent clostridioides; safety; clostridioides difficile; difficile infection ... See more keywords
Gastrointestinal Tract Microbiome Dynamics Following Treatment with SER-109, an Investigational Oral Microbiome Therapeutic to Reduce the Recurrence of Clostridium difficile Infection (CDI)
Sign Up to like & getrecommendations! Published in 2017 at "Open Forum Infectious Diseases"
DOI: 10.1093/ofid/ofx163.968
Abstract: Abstract Background Recurrence of CDI occurs within a few weeks after treatment due to antibiotic-induced dysbiosis. SER-109, an investigational, first-in-class microbiome drug, was designed to sustain a clinical response through microbiome restoration with a purified… read more here.
Keywords: employee shareholder; salary stock; seres therapeutics; shareholder salary ... See more keywords